GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » A Plus Biotechnology Co Ltd (ROCO:6918) » Definitions » Peter Lynch Fair Value

A Plus Biotechnology Co (ROCO:6918) Peter Lynch Fair Value : NT$43.54 (As of May. 24, 2025)


View and export this data going back to 2023. Start your Free Trial

What is A Plus Biotechnology Co Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, A Plus Biotechnology Co's PEG is 1. A Plus Biotechnology Co's 5-Year TTM EBITDA Growth Rate is 8.77. A Plus Biotechnology Co's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2025 was NT$4.97. Therefore, the Peter Lynch Fair Value for today is NT$43.54.

As of today (2025-05-24), A Plus Biotechnology Co's share price is NT$99.70. A Plus Biotechnology Co's Peter Lynch fair value is NT$43.54. Therefore, A Plus Biotechnology Co's Price to Peter Lynch Fair Value Ratio for today is 2.29.


The historical rank and industry rank for A Plus Biotechnology Co's Peter Lynch Fair Value or its related term are showing as below:

ROCO:6918' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.85   Med: 1.85   Max: 2.31
Current: 2.29


During the past 6 years, the highest Price to Peter Lynch Fair Value Ratio of A Plus Biotechnology Co was 2.31. The lowest was 1.85. And the median was 1.85.


ROCO:6918's Price-to-Peter-Lynch-Fair-Value is ranked worse than
66.67% of 171 companies
in the Medical Devices & Instruments industry
Industry Median: 1.55 vs ROCO:6918: 2.29

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


A Plus Biotechnology Co Peter Lynch Fair Value Historical Data

The historical data trend for A Plus Biotechnology Co's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

A Plus Biotechnology Co Peter Lynch Fair Value Chart

A Plus Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Peter Lynch Fair Value
Get a 7-Day Free Trial - - - - 43.54

A Plus Biotechnology Co Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 43.54 -

Competitive Comparison of A Plus Biotechnology Co's Peter Lynch Fair Value

For the Medical Devices subindustry, A Plus Biotechnology Co's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


A Plus Biotechnology Co's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, A Plus Biotechnology Co's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where A Plus Biotechnology Co's Price-to-Peter-Lynch-Fair-Value falls into.


;
;

A Plus Biotechnology Co Peter Lynch Fair Value Calculation

A Plus Biotechnology Co's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 8.77 *4.965
=43.54

A Plus Biotechnology Co's EPS without NRI for the trailing twelve months (TTM) uses the latest annual data, which was NT$4.97.

* Note that for companies that do not have enough quarterly data to calculate the 5-Year TTM EBITDA Growth Rate, we use the annual data for the calculation.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


A Plus Biotechnology Co  (ROCO:6918) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 8.77 instead of 15 in this case.

A Plus Biotechnology Co's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=99.70/43.54
=2.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


A Plus Biotechnology Co Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of A Plus Biotechnology Co's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


A Plus Biotechnology Co Business Description

Traded in Other Exchanges
N/A
Address
No. 21, Qiaohe Road, 3rd Floor, Zhonghe District, New Taipei City, TWN
A Plus Biotechnology Co Ltd provides orthopedic implants. It engages in the research and development of orthopedic medical products. Aplus locking plate systems feature superior anatomical bone curves and 5-axis CNC manufacturing technology.

A Plus Biotechnology Co Headlines

No Headlines